SNCA and Alzheimer disease: Given the frequency of Lewy body co‐pathology in AD, we agree with the inclusion of alpha synuclein as a biomarker for non‐AD co‐pathology in AD, especially given its potential impact on the clinical course (e.g., Levin et al2).